AlloVir, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vikas Sinha CPA,
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1100 Winter Street Waltham MA United States of America 02451
- IPO Date
- Jul 30, 2020
- CIK
- 0001754068
- Website
- allovir.com
- Similar Companies
- Business
- AlloVir, Inc. (Nasdaq: ALVR) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, and founded in 2013 as a successor to ViraCyte, Inc., which develops allogeneic, off-the-shelf, multi-virus specific T cell (VST) therapies to prevent and treat life-threatening viral infections in immunocompromised patients, including those post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). The company's lead product candidate, posoleucel (ALVR105), is an investigational multi-VST therapy targeting six viruses—BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus—and is under evaluation in a Phase 3 clinical trial for preventing clinically significant viral infections following allogeneic HSCT; its pipeline also includes ALVR106 targeting respiratory viruses such as influenza, parainfluenza, respiratory syncytial virus, and human metapneumovirus, ALVR109 (formerly ALVR107) for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108. AlloVir leverages a proprietary VST manufacturing platform enabling rapid production of single- and multi-virus specific T cells from healthy donors for off-the-shelf use, addressing unmet needs in viral diseases affecting pediatric and adult patients with T cell deficiencies across the United States and global clinical trial sites. In recent major developments, AlloVir announced a strategic restructuring in early 2024 with workforce reductions of approximately 95% to extend its cash runway amid challenging market conditions and Phase 3 trial setbacks, reported $134.6 million in cash, equivalents, and investments as of September 30, 2024, and completed a transformational all-stock merger with Kalaris Therapeutics, Inc. on March 18, 2025, resulting in the combined entity operating as Kalaris Therapeutics, Inc. (Nasdaq: KLRS) focused on retinal diseases with approximately $100 million in cash to fund operations into Q4 2026, where pre-merger AlloVir stockholders own about 25% of the new company.
Head to Head Review: AlloVir (NASDAQ:ALVR) versus SQZ Biotechnologies (NYSE:SQZ)
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders
ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation
Kalaris Announces Closing of Merger with AlloVir
Kalaris and AlloVir Announce Stockholder Approval of Merger
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders